STAT+: Cadence raises $100 million to automate chronic disease care with regulated AI
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Cadence raised $100 million in a round led by Spark Capital, valuing the chronic disease management company at $1.23 billion as it seeks to expand and automate clinician workflows with AI.
- Cadence's core billing model — charging insurers monthly for remote patient monitoring — has drawn scrutiny from the federal health department's watchdog and from UnitedHealthcare, with critics arguing the framework is ripe for abuse and may support low-quality care.
- Cadence currently manages over 100,000 patients referred by more than 20 health system customers, relying on devices like blood pressure cuffs and hundreds of clinicians to monitor hypertension, diabetes, and heart failure.
- CEO Chris Altchek said the new capital will fund efforts to automate a significant portion of human clinician work, potentially transforming how the company delivers care at scale.
- The reimbursement framework underpinning most of Cadence's revenue faces an uncertain future, raising the stakes on whether AI-driven automation can sustain growth if the payment model is curtailed.
Why it matters: Cadence's $1.23 billion valuation lands while its primary revenue stream — monthly remote-monitoring billing — is under fire from both the federal health watchdog and UnitedHealthcare, giving the company a narrow window to prove AI automation can scale care before the reimbursement model it depends on is restricted.
Ask SkimNews
